Thymosin alpha-1 vs Thymosin beta-4
How they differ
- FDA status. Thymosin alpha-1: Not FDA-approved; FDA advised against adding it to the compounding list.1,2,3 Thymosin beta-4: No FDA approval reported.3,4
- FDA compounding safety-risk page. Thymosin alpha-1: listed.3 Thymosin beta-4: not listed.3
Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.
Side by side
| Topic | Thymosin alpha-1 | Thymosin beta-4 |
|---|---|---|
| What it is | A 28-amino-acid peptide with an acetylated N-terminus, originally isolated from a thymus extract; FDA describes thymalfasin as a chemically synthesized version.1 | Human thymosin beta-4, also recorded as TMSB4 and TB4X in FDA’s substance registry.4 |
| FDA status | Not FDA-approved Not FDA-approved; FDA advised against adding it to the compounding list1,2,3 Not FDA-approved. FDA’s 2024 evaluation states that it is not a component of an FDA-approved drug, and FDA lists it among compounding substances that may present significant safety risks.1,3 | Not FDA-approved No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page lists a thymosin beta-4 fragment, TB-500, among withdrawn nominations, but not thymosin beta-4 itself.3,4 |
| HHS compounding policy, October 30, 2026 | Not among the six peptides the policy lists.5 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin alpha-1 is not among them.5,6 | Not among the six peptides the policy lists.5 HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Thymosin beta-4 is not among them; TB-500 is a fragment of it.5,6 |
| FDA compounding safety-risk page | Listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists thymosin alpha-1 among substances whose nominations were withdrawn, citing a possible significant risk of immune reactions and inadequate safety information.3 | Not listed. FDA’s compounding safety-risk page, current as of April 22, 2026, lists “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among withdrawn nominations with possible safety risks. It does not list full-length thymosin beta-4.3 |
| Kinds of studies cited | Smaller controlled human trials
| Smaller controlled human trials
|
| Records collected | 18 ClinicalTrials.gov records and 30 PubMed records collected | 7 ClinicalTrials.gov records and 25 PubMed records collected |
| Area of study | ||
| Latest dated events |
|
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 2December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 4Thymosin beta-4 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 5HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 6Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
- 7Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model (2015) · PMID 26056426 ↗
Clinical Ophthalmology · Official source · Source checked November 15, 2026
- 8RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (2022) · PMID 36613994 ↗
International Journal of Molecular Sciences · Official source · Source checked November 15, 2026